Literature DB >> 35905484

UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies Summary of changes.

Andrea Kokorovic1, Alan I So2, Hosam Serag2, Christopher French3, Robert J Hamilton4, Jason P Izard5, Jasmir G Nayak6, Frédéric Pouliot7, Fred Saad1, Bobby Shayegan8, Armen Aprikian9, Ricardo A Rendon10.   

Abstract

Entities:  

Year:  2022        PMID: 35905484      PMCID: PMC9343159          DOI: 10.5489/cuaj.8007

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   2.052


× No keyword cloud information.
  3 in total

1.  Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.

Authors:  Andrea Kokorovic; Alan I So; Hosam Serag; Christopher French; Robert J Hamilton; Jason P Izard; Jasmir G Nayak; Fréderic Pouliot; Fred Saad; Bobby Shayegan; Armen Aprikian; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2021-06       Impact factor: 1.862

2.  Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.

Authors:  Renato D Lopes; Celestia S Higano; Susan F Slovin; Adam J Nelson; Robert Bigelow; Per S Sørensen; Chiara Melloni; Shaun G Goodman; Christopher P Evans; Jan Nilsson; Deepak L Bhatt; Noel W Clarke; Tine K Olesen; Belinda T Doyle-Olsen; Henriette Kristensen; Lauren Arney; Matthew T Roe; John H Alexander
Journal:  Circulation       Date:  2021-08-30       Impact factor: 39.918

3.  Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Authors:  Neal D Shore; Fred Saad; Michael S Cookson; Daniel J George; Daniel R Saltzstein; Ronald Tutrone; Hideyuki Akaza; Alberto Bossi; David F van Veenhuyzen; Bryan Selby; Xiaolin Fan; Vicky Kang; Jackie Walling; Bertrand Tombal
Journal:  N Engl J Med       Date:  2020-05-29       Impact factor: 91.245

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.